Luminescence Detection Reagents for Viral Assays
Closed Pre-Solicitation Posted
- Solicitation number
- 75N95023Q00393
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Fitchburg, Wisconsin 53711, United States
Notice details come from SAM.gov. Updated .
Notice text
INTRODUCTION
PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION.
THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) at the National Insitutes of Health (NIH) on behalf of the National Center for Advancing Translational Sciences (NCATS) intends to negotiate and award a purchase order for luminescence detection reagents for viral assays to: Promega Corporation, 2800 Woods Hollow Rd., Fitchburg, WI 53711-5300. Only this suggested source can furnish the requirements, to the exclusion of other sources, because NCATS has used this product for optimizing HTS development. Utilizing alternatives would jeopardize scientific continuity of ongoing data and research.
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE
The intended procurement is classified under NAICS code 325413, In-Vitro Diagnostic Substance Manufacturing, with a Size Standard of 1,250 employees.
REGULATORY AUTHORITY
The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) currently in effect at https://www.acquisition.gov/
STATUTORY AUTHORITY
This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures.
DESCRIPTION OF REQUIREMENT
Project Description
See Attachment 1 – Purchase Description.
Purpose and Objectives
HTS viral detection assays have previously been optimized at NCATS for viruses such as Rift Valley Fever Virus and Sars-CoV2 using these luminescent detection reagents. The objective is to use these reagents to screen more internal libraries and validate hits from previous screens.
Delivery Date
July 20, 2023
CLOSING STATEMENT
This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice.
Responses to this Notice must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement.
In addition the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
All responses must be received by 09:00 AM EDT June 12, 2023.Responses must be emailed to the Contracting Officer at mark.mcnally@nih.gov and reference the Notice ID 75N95023Q00393.
“All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.”
Files
| File | Type | Posted |
|---|---|---|
| Attachment_01_Purchase_Description.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity